TY  - GEN
AU  - Korn, Stephanie
AU  - Bourdin, Arnaud
AU  - Chupp, Geoffrey
AU  - García-Cosío, Borja
AU  - Arbetter, Doug
AU  - Shah, Mihir
AU  - Garcia Gil, Esther
PY  - 2021
DO  - 10.1016/j.jaip.2021.07.058
SN  - 2213-2198
UR  - https://hdl.handle.net/20.500.12105/23188
AB  - BACKGROUND: Benralizumab is an IL-5R alpha-directed monoclonal antibody indicated for patients with severe, uncontrolled eosinophilic asthma. OBJECTIVE: To evaluate the long-term safety and tolerability of benralizumab among adults treated for up to 5...
LA  - eng
PB  - Elsevier
KW  - Asthma
KW  - Exacerbation
KW  - Benralizumab
KW  - Integrated analysis
KW  - Eosinophils
KW  - Asthma
KW  - Disease Progression
KW  - Eosinophils
KW  - Anti-Asthmatic Agents
KW  - Humans
KW  - Antibodies, Monoclonal, Humanized
KW  - Double-Blind Method
TI  - Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years
TY  - research article
ER  -